Building on success: New AMPLICITY trial opens at Epworth
A new clinical trial for people with metastatic pancreatic cancer is now open at the Jreissati Pancreatic Centre at Epworth. The trial, known as AMPLICITY, is exploring whether a new Australian-developed medicine from Amplia Therapeutics Limited can make chemotherapy more effective for people with pancreatic cancer.
A promising next step in treatment
The study will investigate whether the drug AMP945 (narmafotinib), when taken with a standard chemotherapy combination known as modified FOLFIRINOX, can improve treatment outcomes for people who have recently been diagnosed with metastatic pancreatic cancer. It is designed as a first-line treatment, meaning it is offered before other therapies have been used.
AMP945 was also used in Amplia’s earlier ACCENT trial, where AMP945 was used with a different chemotherapy regimen. Earlier this year, one patient in that study showed no sign of cancer after treatment and surgery.
Taking part in the trial
AMPLICITY is open at only two sites in Australia: the Jreissati Pancreatic Centre at Epworth in Victoria and GenesisCare in New South Wales. At Epworth, the study is available to both public and private patients, as well as individuals living interstate. For patients who live outside Melbourne, the Centre may be able to help with travel or accommodation support.
AMPLICITY offers a new treatment opportunity for people with limited options. By joining the trial, patients can access promising therapies while contributing to research that may benefit others in the future.
We saw something remarkable in the ACCENT study, and it gave us a new sense of what might be possible. With AMPLICITY, we are hoping to take that one powerful result and turn it into something we can offer more patients.
Dr Prasad Cooray, principal investigator at Epworth HealthCare
Pancreatic cancer remains one of the most difficult cancers to treat. But research is changing what the future may look like. Trials like AMPLICITY help turn new discoveries into real options for people affected by pancreatic cancer.